Patent 11878049

Assignment history

Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.

Active provider: Google · gemini-2.5-flash

Ownership chain (2)

Asserters network →

Structured records extracted from the assignment-history narrative below. Each entity links to its full ownership-network profile.

  1. ? · recorded 2020-10-16 · Assignment of Assignors Interest

    Prakash, Chandra Agarwal; IYER, VARSHA VENKATACHALAM; YANG, HUAAGIOS PHARMACEUTICALS, INC.

    Initial assignment of patent rights from multiple inventors to the corporate assignee

  2. ? · recorded 2022-11-11 · Assignment of Assignors Interest

    IYER, VARSHA VENKATACHALAMAGIOS PHARMACEUTICALS, INC.

    Subsequent assignment of patent rights from a single inventor to the corporate assignee, likely a corrective or clarifying record

Assignment history

Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.

✓ Generated

Inventors

  • Varsha Venkatachalam Iyer (Agios Pharmaceuticals Inc.)
  • Chandra Agarwal Prakash (Agios Pharmaceuticals Inc.)
  • Hua Yang (Agios Pharmaceuticals Inc.)

All named inventors were employed by the original assignee, Agios Pharmaceuticals Inc., at the time of filing, as indicated by the assignment records to Agios Pharmaceuticals, Inc.. There are no unusual patterns observed regarding inventor departures.

Original assignee

Agios Pharmaceuticals Inc. is the original assignee named on the issued patent US11878049. Agios Pharmaceuticals Inc. is a biotechnology company focused on developing therapies for rare diseases, including hemolytic anemias. They have shipped a product embodying the claims, specifically mitapivat (marketed as PYRUKYND), which is a pyruvate kinase R (PKR) activator used to treat pyruvate kinase deficiency (PKD). As of the current date, Agios Pharmaceuticals Inc. is an operating company.

Assignment timeline

The Google Patents legal events for US11878049 indicate the following assignments from the inventors to the assignee:

  • 2020-10-16 (execution date not explicitly stated, but recorded on this date) / recorded 2020-10-16

    • Conveyance: Assignment of Assignors Interest
    • Assignor: Prakash, Chandra Agarwal, IYER, VARSHA VENKATACHALAM, YANG, HUA (Inventors)
    • Assignee: AGIOS PHARMACEUTICALS, INC.
    • Correspondent: Not specified in the provided patent text.
    • Context: Initial assignment of patent rights from multiple inventors to the corporate assignee.

  • 2022-11-11 (execution date not explicitly stated, but recorded on this date) / recorded 2022-11-11

    • Conveyance: Assignment of Assignors Interest
    • Assignor: IYER, VARSHA VENKATACHALAM (Inventor)
    • Assignee: AGIOS PHARMACEUTICALS, INC.
    • Correspondent: Not specified in the provided patent text.
    • Context: Subsequent assignment of patent rights from a single inventor to the corporate assignee, likely a corrective or clarifying record.

No further transfers between corporate entities are indicated in the provided legal event data.

Timeline diagram

timeline
    title Ownership of US 11878049
    2020 : Application filed by Agios
         : Inventors assigned to Agios
    2022 : Inventor Iyer assigned to Agios
    2024 : Patent granted to Agios

NPE / troll-pattern signals

  1. Shell-entity transfer — Not present. The patent remains with the original operating company, Agios Pharmaceuticals Inc., which develops and markets pharmaceutical products.
  2. Known asserter in the chain — Not present. Agios Pharmaceuticals Inc. is not identified on common NPE lists.
  3. Repeat correspondent across the chain — Unclear. The correspondent information (attorney name, firm, address) is not explicitly provided in the Google Patents legal events for the assignments, preventing an assessment of recurrence.
  4. Cascading transfers — Not present. The assignments recorded are from individual inventors to the sole corporate assignee, Agios Pharmaceuticals Inc., not consecutive transfers through multiple LLCs.
  5. Pre-litigation transfer — Not present. There is no indication of an infringement suit being filed.
  6. Bankruptcy fire-sale — Not present. Agios Pharmaceuticals Inc. is an active operating company.
  7. Privateering — Not present. The patent remains with the operating company, and there is no evidence of transfer to an NPE for assertion.
  8. Defensive aggregator (anti-NPE) — Not present. The patent is owned by an operating company, not a defensive aggregator.

Verdict

Insufficient data. The available records only show the initial assignments from the individual inventors to the original corporate assignee, Agios Pharmaceuticals Inc. There are no subsequent corporate transfers that would indicate a change in ownership or involvement of any NPEs. Without information on further assignments or litigation activity, it is not possible to classify this patent as being involved in NPE assertion.

USPTO Assignment Center search for US11878049: https://assignmentcenter.uspto.gov/patent/index.html?pno=11878049

Generated 5/19/2026, 6:45:52 AM